Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) shares rose 12% during trading on Monday . The company traded as high as $10.50 and last traded at $10.4680. Approximately 395,352 shares changed hands during trading, a decline of 54% from the average daily volume of 852,425 shares. The stock had previously closed at $9.35.
Analyst Upgrades and Downgrades
KYTX has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Kyverna Therapeutics in a report on Thursday, April 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Kyverna Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $28.67.
Check Out Our Latest Analysis on KYTX
Kyverna Therapeutics Price Performance
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last released its quarterly earnings data on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, meeting analysts’ consensus estimates of ($0.80). Analysts anticipate that Kyverna Therapeutics, Inc. will post -3.18 EPS for the current fiscal year.
Hedge Funds Weigh In On Kyverna Therapeutics
Large investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio bought a new stake in Kyverna Therapeutics during the third quarter valued at approximately $28,000. Qube Research & Technologies Ltd bought a new stake in Kyverna Therapeutics during the second quarter valued at approximately $43,000. Rhumbline Advisers lifted its position in Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares during the last quarter. Ameriprise Financial Inc. bought a new stake in Kyverna Therapeutics during the third quarter valued at approximately $77,000. Finally, Bank of America Corp DE lifted its position in Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after purchasing an additional 6,400 shares during the last quarter. 18.08% of the stock is currently owned by institutional investors.
About Kyverna Therapeutics
Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.
The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.
Read More
- Five stocks we like better than Kyverna Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
